170 related articles for article (PubMed ID: 29137286)
1. Fibroblast growth factor modulates mast cell recruitment in a murine model of prostate cancer.
Ronca R; Tamma R; Coltrini D; Ruggieri S; Presta M; Ribatti D
Oncotarget; 2017 Oct; 8(47):82583-82592. PubMed ID: 29137286
[TBL] [Abstract][Full Text] [Related]
2. Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer.
Ronca R; Alessi P; Coltrini D; Di Salle E; Giacomini A; Leali D; Corsini M; Belleri M; Tobia C; Garlanda C; Bonomi E; Tardanico R; Vermi W; Presta M
J Pathol; 2013 Jun; 230(2):228-38. PubMed ID: 23424081
[TBL] [Abstract][Full Text] [Related]
3. Long Pentraxin 3-Mediated Fibroblast Growth Factor Trapping Impairs Fibrosarcoma Growth.
Rodrigues PF; Matarazzo S; Maccarinelli F; Foglio E; Giacomini A; Silva Nunes JP; Presta M; Dias AAM; Ronca R
Front Oncol; 2018; 8():472. PubMed ID: 30443492
[TBL] [Abstract][Full Text] [Related]
4. Long Pentraxin-3 Modulates the Angiogenic Activity of Fibroblast Growth Factor-2.
Presta M; Foglio E; Churruca Schuind A; Ronca R
Front Immunol; 2018; 9():2327. PubMed ID: 30349543
[TBL] [Abstract][Full Text] [Related]
5. The Autocrine FGF/FGFR System in both Skin and Uveal Melanoma: FGF Trapping as a Possible Therapeutic Approach.
Rezzola S; Ronca R; Loda A; Nawaz MI; Tobia C; Paganini G; Maccarinelli F; Giacomini A; Semeraro F; Mor M; Presta M
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31487962
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer.
Polnaszek N; Kwabi-Addo B; Peterson LE; Ozen M; Greenberg NM; Ortega S; Basilico C; Ittmann M
Cancer Res; 2003 Sep; 63(18):5754-60. PubMed ID: 14522896
[TBL] [Abstract][Full Text] [Related]
7. Long-Pentraxin 3 Affects Primary Cilium in Zebrafish Embryo and Cancer Cells via the FGF System.
Guerra J; Chiodelli P; Tobia C; Gerri C; Presta M
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630309
[TBL] [Abstract][Full Text] [Related]
8. Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy.
Ronca R; Giacomini A; Di Salle E; Coltrini D; Pagano K; Ragona L; Matarazzo S; Rezzola S; Maiolo D; Torrella R; Moroni E; Mazzieri R; Escobar G; Mor M; Colombo G; Presta M
Cancer Cell; 2015 Aug; 28(2):225-39. PubMed ID: 26267536
[TBL] [Abstract][Full Text] [Related]
9. Long pentraxin-3 inhibits epithelial-mesenchymal transition in melanoma cells.
Ronca R; Di Salle E; Giacomini A; Leali D; Alessi P; Coltrini D; Ravelli C; Matarazzo S; Ribatti D; Vermi W; Presta M
Mol Cancer Ther; 2013 Dec; 12(12):2760-71. PubMed ID: 24130051
[TBL] [Abstract][Full Text] [Related]
10. Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo.
Camozzi M; Zacchigna S; Rusnati M; Coltrini D; Ramirez-Correa G; Bottazzi B; Mantovani A; Giacca M; Presta M
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1837-42. PubMed ID: 16020751
[TBL] [Abstract][Full Text] [Related]
11. Pentraxin 3 Inhibits the Angiogenic Potential of Multiple Myeloma Cells.
Ronca R; Taranto S; Corsini M; Tobia C; Ravelli C; Rezzola S; Belleri M; De Cillis F; Cattaneo A; Presta M; Giacomini A
Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34066669
[TBL] [Abstract][Full Text] [Related]
12. A long pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven steroid hormone-regulated cancers.
Giacomini A; Matarazzo S; Pagano K; Ragona L; Rezzola S; Corsini M; Di Salle E; Presta M; Ronca R
Oncotarget; 2015 May; 6(15):13790-802. PubMed ID: 25912421
[TBL] [Abstract][Full Text] [Related]
13. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer.
Giri D; Ropiquet F; Ittmann M
Clin Cancer Res; 1999 May; 5(5):1063-71. PubMed ID: 10353739
[TBL] [Abstract][Full Text] [Related]
14. Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumors.
Leali D; Alessi P; Coltrini D; Ronca R; Corsini M; Nardo G; Indraccolo S; Presta M
Mol Cancer Ther; 2011 Sep; 10(9):1600-10. PubMed ID: 21764903
[TBL] [Abstract][Full Text] [Related]
15. The natural FGF-trap long pentraxin 3 inhibits lymphangiogenesis and lymphatic dissemination.
Turati M; Giacomini A; Rezzola S; Maccarinelli F; Gazzaroli G; Valentino S; Bottazzi B; Presta M; Ronca R
Exp Hematol Oncol; 2022 Nov; 11(1):84. PubMed ID: 36320051
[TBL] [Abstract][Full Text] [Related]
16. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
17. The role of fibroblast growth factors and their receptors in prostate cancer.
Kwabi-Addo B; Ozen M; Ittmann M
Endocr Relat Cancer; 2004 Dec; 11(4):709-24. PubMed ID: 15613447
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor expression induces FGF2, FGF-binding protein production, and FGF2 release in prostate carcinoma cells: role of FGF2 in growth, survival, and androgen receptor down-modulation.
Rosini P; Bonaccorsi L; Baldi E; Chiasserini C; Forti G; De Chiara G; Lucibello M; Mongiat M; Iozzo RV; Garaci E; Cozzolino F; Torcia MG
Prostate; 2002 Dec; 53(4):310-21. PubMed ID: 12430142
[TBL] [Abstract][Full Text] [Related]
19. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
Ronca R; Giacomini A; Rusnati M; Presta M
Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
[TBL] [Abstract][Full Text] [Related]
20. Rapid tumor development and potent vascularization are independent events in carcinoma producing FGF-1 or FGF-2.
Billottet C; Janji B; Thiery JP; Jouanneau J
Oncogene; 2002 Nov; 21(53):8128-39. PubMed ID: 12444548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
